Список литературы

1. Программное лечение заболеваний системы крови, под ред. Савченко В.Г. М.: Практика; 2012: 155 - 245.

2. Савченко В.Г., Паровичникова Е.Н. Глава "Острые лейкозы" в книге "Клиническая онкогематология", под ред. Волковой М.А., М.: Медицина; 2001: 156 - 207.

3. Swerdlow S., Campo E., Yarris N.L. et al., eds. WHO classification of tumors of hematopoietic and lymphoid tissues. Geneva: WHO PRESS; 2008: 110 - 55.

4. H., Estey E.H., Amadori S., Appelbaum F.R (https://www.ncbi.nlm.nih.gov/pubmed?term=appelbaum%2520fr%255bauthor%255d&cauthor=true&cauthor_uid=19880497)., Buchner T (https://www.ncbi.nlm.nih.gov/pubmed?term=b%25c3%25bcchner%2520t%255bauthor%255d&cauthor=true&cauthor_uid=19880497)., Burnett A.K (https://www.ncbi.nlm.nih.gov/pubmed?term=burnett%2520ak%255bauthor%255d&cauthor=true&cauthor_uid=19880497)., et al.; European LeukemiaNet (https://www. ncbi. nlm. nih.gov/pubmed?term=european%2520leukemianet%255bcorporate%2520author%255d). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115(3): 453--74. doi: 10.1182/blood-2009-07-235358.

5. National Comprehensive Cancer Network (NCCN) GUIDELINES FOR AML TREATMENT Version 2.2013. http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf (http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf)

1. Cornelissen J.J., Gratwohl A., Schlenk R.F., Sierra J (https://www.ncbi.nlm.nih.gov/pubmed?term=sierra%2520j%255bauthor%255d&cauthor=true&cauthor_uid=22949046)., M (https://www.ncbi.nlm.nih.gov/pubmed?term=bornh%25c3%25a4user%2520m%255bauthor%255d&cauthor=true&cauthor_uid=22949046)., Juliusson G (https://www.ncbi.nlm.nih.gov/pubmed?term=juliusson%2520g%255bauthor%255d&cauthor=true&cauthor_uid=22949046)., et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat. Rev. Clin. Oncol. 2012; 9(10): 579 - 90. doi: 10.1038/nrclinonc.2012.150.

2. Averbuch D (https://www.ncbi.nlm.nih.gov/pubmed?term=averbuch%2520d%255bauthor%255d&cauthor=true&cauthor_uid=24323983)., (http://www.ncbi.nlm.nih.gov/pubmed?term=cordonnier%2520c%255bauthor%255d&cauthor=true&cauthor_uid=24323983)Orasch C (https://www.ncbi.nlm.nih.gov/pubmed?term=orasch%2520c%255bauthor%255d&cauthor=true&cauthor_uid=24323983)., (http://www.ncbi.nlm.nih.gov/pubmed?term=cordonnier%2520c%255bauthor%255d&cauthor=true&cauthor_uid=24323983)Cordonnier C (https://www.ncbi.nlm.nih.gov/pubmed?term=cordonnier%2520c%255bauthor%255d&cauthor=true&cauthor_uid=24323983)., (http://www.ncbi.nlm.nih.gov/pubmed?term=cordonnier%2520c%255bauthor%255d&cauthor=true&cauthor_uid=24323983)Livermore D.M (https://www.ncbi.nlm.nih.gov/pubmed?term=livermore%2520dm%255bauthor%255d&cauthor=true&cauthor_uid=24323983)., (http://www.ncbi.nlm.nih.gov/pubmed?term=cordonnier%2520c%255bauthor%255d&cauthor=true&cauthor_uid=24323983)Mikulska M (https://www.ncbi.nlm.nih.gov/pubmed?term=mikulska%2520m%255bauthor%255d&cauthor=true&cauthor_uid=24323983)., (http://www.ncbi.nlm.nih.gov/pubmed? term=cordonnier%2520c%255bauthor%255d&cauthor=true&cauthor_uid=24323983)Viscoli C (https://www.ncbi.nlm.nih.gov/pubmed?term=viscoli%2520c%255bauthor%255d&cauthor=true&cauthor_uid=24323983)., et al.; (http://www.ncbi.nlm.nih.gov/pubmed?term=cordonnier%2520c%255bauthor%255d&cauthor=true&cauthor_uid=24323983)ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN (https://www.ncbi.nlm.nih.gov/pubmed? term=ecil4%252c%2520a%2520joint%2520venture%2520of%2520ebmt%252c%2520eortc%252c%2520ichs%252c%2520esgich%252 European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. (http://www.ncbi.nlm.nih.gov/pubmed?term=cordonnier%2520c%255bauthor%255d&cauthor=true&cauthor_uid=24323983) Haematologica. (http://www.ncbi.nlm.nih.gov/pubmed/24323983#%23) 2013; 98(12): 1826 - 35. doi: 10.3324/haematol.2013.091025

3. ECIL-4, 2011; Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011. D. Averbuch et al. Haematologica 2013.

4. ECIL-5, 2013; https://www.ebmt.org/Contents/Resources/Library/ECIL/(https://www.ebmt.org/Contents/Resources/Library/ECIL/)Documents/2014ECIL5/ECIL5antifungalprophylaxis20062014Final.pdf